To CHOP or not to CHOP... is that the question?CABANILLAS, F.Annals of oncology. 1992, Vol 3, Num 3, pp 183-185, issn 0923-7534Article

Chemotherapy as definitive treatment of stage I-II large cell and diffuse mixed lymphomasCABANILLAS, F.Hematological oncology. 1985, Vol 3, Num 1, pp 25-31, issn 0278-0232Article

IFOSFAMIDE, METHOTREXATE, AND VINCRISTINE (IMV) COMBINATION CHEMOTHERAPY AS SECONDARY TREATMENT FOR PATIENTS WITH MALIGNANT LYMPHOMACABANILLAS F; RODRIGUEZ V; BODEY GP et al.1980; CANCER TREATM. REP.; USA; DA. 1980; VOL. 64; NO 8-9; PP. 933-937; BIBL. 14 REF.Article

IMPROVEMENT IN COMPLETE RESPONSE RATE, DURATION OF RESPONSE AND SURVIVAL WITH ADRIAMYCIN COMBINATION CHEMOTHERAPY FOR NON-HODGKIN LYMPHOMA: A PROGNOSTIC FACTOR COMPARISON OF TWO REGIMENSCABANILLAS F; RODRIGUEZ V; FREIREICH EJ et al.1978; MED. PEDIATR. ONCOL.; USA; DA. 1978; VOL. 4; NO 4; PP. 321-331; BIBL. 13 REF.Article

MANAGEMENT WITH CHEMOTHERAPY ONLY OF STAGE I AND II MALIGNANT LYMPHOMA OF AGGRESSIVE HISTOLOGIC TYPESCABANILLAS F; BODEY GP; FREIREICH EJ et al.1980; CANCER; ISSN 0008-543X; USA; DA. 1980; VOL. 46; NO 11; PP. 2356-2359; BIBL. 14 REF.Article

The radiologic assessment of the lymphoma patient from the standpoint of the clinicianCABANILLAS, F; FULLER, L. M.The Radiologic clinics of North America. 1990, Vol 28, Num 4, pp 683-695, issn 0033-8389Article

CENTRAL NERVOUS SYSTEM RELAPSE IN MALIGNANT LYMPHOMAS RISK FACTORS AND IMPLICATIONS FOR PROPHYLAXISLITAM JP; CABANILLAS F; SMITH TL et al.1979; BLOOD; USA; DA. 1979; VOL. 54; NO 6; PP. 1249-1257; BIBL. 16 REF.Article

EFFECTIVE COMBINATION CHEMOTHERAPY OF ADULT MALIGNANT HISTIOCYTOSIS (HISTIOCYTIC MEDULLARY RETICULOSIS).CABANILLAS F; RODRIGUEZ V; VALDIVIESO M et al.1978; MED. PEDIATR. ONCOL.; U.S.A.; DA. 1978; VOL. 4; NO 1; PP. 29-34; BIBL. 19 REF.Article

The role of topoisomerase-I inhibitors in the treatment of non-Hodgkin's lymphomaCABANILLAS, F.Seminars in hematology. 1999, Vol 36, Num 4, pp 11-15, issn 0037-1963, SUP8Article

MINE-ESHAP salvage therapy for recurrent and refractory lymphomasCABANILLAS, F; RODRIGUEZ, M. A.Seminars in hematology. 1994, Vol 31, Num 2, issn 0037-1963, p. 30, SUP3Conference Paper

NODULAR MALIGNANT LYMPHOMAS. FACTORS AFFECTING COMPLETE RESPONSE RATE AND SURVIVALCABANILLAS F; SMITH T; BODEY GP et al.1979; CANCER; USA; DA. 1979; VOL. 44; NO 6; PP. 1983-1989; BIBL. 15 REF.Article

PHASE II TRIAL OF AZIRIDINYLBENZOQUINONE (AZQ) IN PATIENTS WITH REFRACTORY LYMPHOMA = ESSAI PHASE II DE L'AZIRIDINYLBENZOQUINONE (AZQ) DANS LES LYMPHOMES REFRACTAIRESMCLAUGHLIN P; CABANILLAS F; BEDIKIAN AY et al.1983; CANCER TREATMENT REPORTS; ISSN 0361-5960; USA; DA. 1983; VOL. 67; NO 5; PP. 507-508; BIBL. 5 REF.; GRAPHArticle

INTENSIVE INDUCTION CHEMOTHERAPY OF EXTENSIVE SMALL CELL BRONCHOGENIC CARCINOMA IN PROTECTED ENVIRONMENT PROPHYLACTIC ANTIBIOTIC UNITS: A PRELIMINARY REPORTVALDIVIESO M; CABANILLAS F; BARKLEY HT et al.1980; INT. J. RADIAT. ONCOL., BIOL., PHYS.; ISSN 0360-3016; USA; DA. 1980; VOL. 6; NO 8; PP. 1087-1092; BIBL. 13 REF.Conference Paper

IMVP-16: AN EFFECTIVE REGIMEN FOR PATIENTS WITH LYMPHOMA WHO HAVE RELAPSED AFTER INITIAL COMBINATION CHEMOTHERAPYCABANILLAS F; HAGEMEISTER FB; BODEY GP et al.1982; BLOOD; ISSN 0006-4971; USA; DA. 1982; VOL. 60; NO 3; PP. 693-697; BIBL. 23 REF.Article

INITIAL EXPERIENCE WITH AMSA AS SINGLE AGENT TREATMENT AGAINST MALIGNANT LYMPHOPROLIFERATIVE DISORDERSCABANILLAS F; LEGHA SS; BODEY GP et al.1981; BLOOD; ISSN 0006-4971; USA; DA. 1981; VOL. 57; NO 3; PP. 614-616; BIBL. 9 REF.Article

PROTECTED ENVIRONMENT-PROPHYLACTIC ANTIBIOTIC PROGRAM FOR MALIGNANT LYMPHOMA: RANDOMIZED TRIAL DURING CHEMOTHERAPY TO INDUCE REMISSIONBODEY GP; RODRIGUEZ V; CABANILLAS F et al.1979; AMER. J. MED.; USA; DA. 1979; VOL. 66; NO 1; PP. 74-81; BIBL. 18 REF.Article

COMBINATION CHEMOTHERAPY ("CHOP-BLEO") IN ADVANCED (NON-HODGKIN) MALIGNANT LYMPHOMA.RODRIGUEZ V; CABANILLAS F; BURGESS MA et al.1977; BLOOD; U.S.A.; DA. 1977; VOL. 49; NO 3; PP. 325-333; BIBL. 16 REF.Article

SISOMICIN THERAPY OF INFECTIONS IN CANCER PATIENTSBODEY GP; CABANILLAS F; FELD R et al.1979; CURR. THERAPEUT. RES.; USA; DA. 1979; VOL. 25; NO 6; PP. 814-826; BIBL. 19 REF.Article

LEUKOCYTE INTERFERON-INDUCED TUMOR REGRESSION IN HUMAN METASTATIC BREAST CANCER, MULTIPLE MYELOMA, AND MALIGNANT LYMPHOMAGUTTERMAN JU; BLUMENSCHEIN GR; ALEXANIAN R et al.1980; ANN. INTERN. MED.; ISSN 0003-4819; USA; DA. 1980; VOL. 93; NO 3; PP. 399-406; BIBL. 31 REF.Article

PHASE I STUDY OF MAYTANSINE USING A 3-DAY SCHEDULE.CABANILLAS F; RODRIGUEZ V; HALL SW et al.1978; CANCER TREATM. REP.; U.S.A.; DA. 1978; VOL. 62; NO 3; PP. 425-428; BIBL. 3 REF.Article

T-cell-rich B-cell lymphomaRODRIGUEZ, J; PUGH, W. C; CABANILLAS, F et al.Blood. 1993, Vol 82, Num 5, pp 1586-1589, issn 0006-4971Article

Central nervous system prophylaxis with combined intravenous and intrathecal methotrexate in diffuse lymphoma of aggressive histologic typePEREZ-SOLER, R; SMITH, T. L; CABANILLAS, F et al.Cancer. 1986, Vol 57, Num 5, pp 971-977, issn 0008-543XArticle

9-β-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphomaDANHAUSER, L; PLUNKETT, W; KEATING, M et al.Cancer chemotherapy and pharmacology. 1986, Vol 18, Num 2, pp 145-152, issn 0344-5704Article

Primary lymphoma of the prostate : good outcome with doxorubicin-based combination chemotherapySARRIS, A; DIMOPOULOS, M; PUGH, W et al.The Journal of urology. 1995, Vol 153, Num 6, pp 1852-1854, issn 0022-5347Article

Analysis of the expression of the hybrid gene bcl-2/IgH in follicular lymphomasSOUBEYRAN, P; CABANILLAS, F; MING SHENG LEE et al.Blood. 1993, Vol 81, Num 1, pp 122-127, issn 0006-4971Article